SpringWorks Therapeutics, Inc.

Good morning. My name is Tawanda, and I will be your conference operator today. At this time, I would like to welcome everyone to the SpringWorks Therapeutics first quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. Please limit yourself to one question each. Thank you. I would now like to hand the conference over to Samantha Sandler, Senior Director of Investor Relations at SpringWorks Therapeutics. Samantha, you may now begin the conference.

Thank you, and good morning, everyone. Welcome to SpringWorks Therapeutics first quarter 2024 earnings conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors and Media section of our website at www.springworkstx.com. Joining me today are Saqib Islam, Chief Executive Officer, Bhavesh Asher, Chief Commercial Officer, Dr. Jim Cassidy, Chief Medical Officer, and Frank Perrier, Chief Financial Officer, Dr. Badredeem Idrees, Chief Operating Officer, is also on the line and available during Q&A. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements that are subject to a number of risks and uncertainties. These may cause our actual results to differ materially, including those described in our reports filed with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and SpringWorks disclaims any obligation to update such statements. I will now turn the call over to Saqib.

Thank you, Sam, and thank you all for joining this morning. Today, I'm pleased to share our first quarter performance as well as our progress towards accomplishing our key objectives for 2024 and beyond. A top priority for SpringWorks is to continue to execute on our successful U.S. launch of Oxivio for desmoid tumors. and we are very pleased with our strong start. In the first quarter of 2024, our first full quarter on the market, we reported $21 million in net product revenue. This performance underscores the high unmet need for patients with desmoid tumors, the transformative benefits of Oxivio to these patients, and strong execution across our commercial efforts. We are encouraged by the strong adoption to date and believe there is a meaningful opportunity ahead of us to serve desmoid tumor patients at all stages of their treatment journeys. We are focused on delivering OXIVIO to the broad desmoid tumor community and believe that we are establishing a new standard of care for the treatment of this disease. A second key priority for us is the significant opportunity we see for mirtometinib, our MEK inhibitor, to help a large number of patients with neurofibromatosis type 1 associated plexiform neurofibromas, or NF1PN. We believe mirtimetinib is a potentially best-in-class treatment for both children and adults with these debilitating tumors. We initiated our rolling NDA submission in March of this year, which we expect to position us to have our second approved product by 2025. We are also continuing to progress our broader targeted oncology pipeline, which presents multiple opportunities to advance the standard of care across different patient populations. Our ongoing studies are targeting a variety of indications, including ovarian granulosa cell tumors, multiple myeloma, MAPK mutant solid tumors, and hippo mutant solid tumors, which we will be discussing this morning. Finally, we are in a strong financial position with a balance sheet that is expected to fund our operations through profitability. I'll now turn this call over to Bhavesh, our Chief Commercial Officer, to discuss our commercial progress this year. Bhavesh?